1. Pink Sheet
  2. >>Geography
  3. >>Europe

Roche Among EU Fast-Track Hopefuls With Lymphoma Bispecific Mosunetuzumab

 
• By Neena Brizmohun

Two companies are set to learn whether the European Medicines Agency will agree that their planned EU marketing applications merit an accelerated assessment.

The EMA can review marketing applications faster under its accelerated assessment mechanism • Source: Alamy

The European Medicines Agency is expected to decide this week whether to fast track its assessment of the planned EU marketing authorization applications for two investigational products – tabelecleucel (tab-cel) and mosunetuzumab.

Tab‐cel, from Atara Biotherapeutics, is an off-the-shelf, allogeneic T-cell immunotherapy for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

FDA Adcomms Are Back: Four Cancer Drugs, COVID-19 Vaccine Formulations To Get Reviews

 
• By Sue Sutter and Bridget Silverman

The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.